Hospitals can apply for this program if they’re currently enrolled in the 340B Drug Pricing Program, which requires drug manufactureres to provide outpatient medications at reduced prices. To apply, hospitals must also be classified as a Disproportionate Share Hosptial (a hospital that treats patients who don’t have insurance or aren’t eligible for other health care coverage).
Hospitals that participate in this program are required to sign a contract and agree to on-site assessments.
The program includes these medications:
EDURANT®
(rilpivirine) Tablets
INTELENCE®
(etravirine) Tablets
INVOKAMET® †
(canagliflozin/metformin HCI) Tablets
INVOKAMET® XR†
(canagliflozin/metformin HCI) Tablets
INVOKANA®†
(canagliflozin) Tablets
PREZCOBIX®
(darunavir 800mg/cobicistat 150mg) Tablets
PREZISTA®
(darunavir) Tablets
SYMTUZA®
(darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) Tablets
XARELTO® †
(rivaroxaban) Tablets
† Please see full U.S. prescribing information, including Black Box warning for: INVOKAMET®, INVOKAMET® XR, INVOKANA®, XARELTO®
Hospitals can apply online via the HAPAP Portal.